Synergy Pharmaceuticals buy tamam
Zusammenfassung
Diese Einschätzung wurde am 06.04.16 mit einem Endkurs von 2,52 € beendet. Stark abwärts ging es für die BUY Einschätzung von tamam zu Synergy Pharmaceuticals mit einer Rendite von -57,53 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Synergy Pharmaceuticals | - | - | - | - |
iShares Core DAX® | 1,78 % | 3,17 % | 14,88 % | 17,66 % |
iShares Nasdaq 100 | -1,04 % | 1,87 % | 35,46 % | 52,32 % |
iShares Nikkei 225® | -0,33 % | 3,86 % | 14,48 % | 11,46 % |
iShares S&P 500 | 0,85 % | 2,57 % | 31,10 % | 47,44 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Synergy Pharmaceuticals diskutieren
It seems logical to imagine SGYP as a takeover candidate, because
Synergy represents a late-stage, highly risk-mitigated and undervalued name in the biotech sector, as its lead candidate plecanatide has already completed two pivotal Phase 3 trials in chronic idiopathic constipation (CIC) successfully and is slated to be filed for approval by the end of this year.
With ~45 million Americans suffering from chronic constipation and IBS, and companies like Allergan (NYSE:AGN) and Valeant (NYSE:VRX) focusing their marketing efforts on GI treatments, it seems logical to imagine SGYP as a takeover candidate.
Beendete Einschätzungen von tamam zu Synergy Pharmaceuticals
Synergy Pharmaceuticals
25.09.17
13.12.18
13.12.18
Synergy Pharmaceuticals
18.03.17
22.05.17
22.05.17